Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $8.74 USD
Change Today -0.41 / -4.48%
Volume 26.4K
As of 2:13 PM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Ivan Bergstein M.D.

Founder, Chairman, Chief Executive Officer and President ,Stemline Therapeutics, Inc.
AgeTotal Calculated CompensationThis person is connected to 9 board members in 1 different organizations across 1 different industries.

See Board Relationships
49$3,136,100
As of Fiscal Year 2014

Background*

Dr. Ivan Bergstein, M.D. founded Stemline Therapeutics, Inc., in August 2003 and has been its Chairman, President and Chief Executive Officer since August 2003. Dr. Bergstein served as the Medical Director of Keryx Biopharmaceuticals, Inc., (formerly Access Oncology, Inc.), where he was a key member of the team that in-licensed and developed several clinical stage oncology compounds. Prior to this, he served as Senior Biopharmaceuticals Analyst at Cancer Advisors (now ...

Read Full Background

Corporate Headquarters*

750 Lexington Avenue
New York, New York 10022

United States

Phone: 646-502-2311
Fax: 646-389-0968

Board Members Memberships*

2003-Present
Founder, Chairman, Chief Executive Officer and President

Education*

BA
The University of Pennsylvania
MD
Mount Sinai NYU Health

Other Affiliations*

Annual Compensation*

Salary$500,000
Bonus$375,000
Total Annual Compensation$875,000

Stock Options*

Restricted Stock Awards$722,893
Exercisable Options457,408
Exercisable Options Value$6,619,428
Unexercisable Options162,360
Unexercisable Options Value$1,169,833
Total Value of Options$7,789,260
Total Number of Options619,768

Total Compensation*

Total Annual Cash Compensation$950,000
Total Short Term Compensation$875,000
Other Long Term Compensation$722,893
Total Calculated Compensation$3,136,100
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STML:US $8.74 USD -0.41

COMPETITOR COMPENSATION

There is no Competitor Compensation data available.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STEMLINE THERAPEUTICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.